The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Peptide Therapy Market Research Report 2025

Global Peptide Therapy Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1688347

No of Pages : 113

Ask Your Query
Synopsis
Peptide therapy refers to restoring the amount of peptides to stimulate the cellular regeneration system in the body, and can be an excellent complement to small molecule and biotherapeutics as a treatment option under certain conditions. The most common uses of peptide therapy are to help build muscle and reduce fat, increase energy, improve sexual function, and reduce gastrointestinal and musculoskeletal inflammation. The most common prescription peptide combinations naturally boost growth hormone for better recovery. Peptides were initially used only for diagnostics and hormone therapy; however, as technology has advanced, they are now also widely used to treat cancer and chronic metabolic diseases. Peptides are also used in cosmeceutical operations to slow down the skin's aging process. Naturally occurring peptides are strings of amino acids present in all living organisms. Peptide therapy is used to treat various diseases. The peptide acts as an anti-infective growth hormone and even as an ion channel ligand. Peptide therapy can perform the same function. Developments in the global biotech and pharmaceutical industries have proven that peptide therapy can stimulate essential hormones. As we age, our body's endopeptide production is disturbed. Peptide therapy safely and effectively reintroduces important peptides into the body. Peptide therapy can treat neurological problems, diabetes, cancer, heart problems and many other diseases. In addition, peptide therapy can also improve muscle endurance, pain relief, injury recovery and aid in weight loss. During treatment, the peptides are delivered directly into the blood. Peptide therapeutics are growing rapidly in the pharmaceutical and biotech industries. Peptide therapy has grown in popularity in the global nutrition industry in recent years. Moreover, the global healthcare industry has rapidly adopted peptide drug delivery options. Peptide therapy has positively impacted human health by improving stamina and immunity and reducing adverse side effects caused by long-term chronic diseases. Rising geriatric population is the major driving factor for the development of the peptide therapeutics market. Furthermore, technological advancements in the pharmaceutical industry are considered to drive the growth of the market over the forecast period 2023 to 2032. Various peptide conjugates help reduce inflammation, act as antioxidants and promote weight loss. Booming health and nutrition industry is driving the demand for peptide drugs.
Global Peptide Therapy market is projected to reach US$ 62820 million in 2029, increasing from US$ 43110 million in 2022, with the CAGR of 5.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Peptide Therapy market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Peptide Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Eli Lilly
AstraZeneca
Merck
Ipsen
Novo Nordisk
Teva Pharmaceutical Industries
Abbott Laboratories
Sanofi
J & J
Novartis
Takeda
Ferring
AbbVie
Heinis
Hemmo
Emcure Pharmaceutical
Cipla
Gland Pharma
Troikaa Pharmaceuticals
Biological E
Segment by Type
Parenteral Route of Administration
Mucosal Route of Administration
Oral Route of Administration
Transdermal Route of Administration
Segment by Application
Cancer
Cardiovascular Diseases
Gastrointestinal Disorders
Metabolic Disorders
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Peptide Therapy report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index
1 Peptide Therapy Market Overview
1.1 Product Overview and Scope of Peptide Therapy
1.2 Peptide Therapy Segment by Type
1.2.1 Global Peptide Therapy Market Value Comparison by Type (2023-2029)
1.2.2 Parenteral Route of Administration
1.2.3 Mucosal Route of Administration
1.2.4 Oral Route of Administration
1.2.5 Transdermal Route of Administration
1.3 Peptide Therapy Segment by Application
1.3.1 Global Peptide Therapy Market Value by Application: (2023-2029)
1.3.2 Cancer
1.3.3 Cardiovascular Diseases
1.3.4 Gastrointestinal Disorders
1.3.5 Metabolic Disorders
1.3.6 Others
1.4 Global Peptide Therapy Market Size Estimates and Forecasts
1.4.1 Global Peptide Therapy Revenue 2018-2029
1.4.2 Global Peptide Therapy Sales 2018-2029
1.4.3 Global Peptide Therapy Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Peptide Therapy Market Competition by Manufacturers
2.1 Global Peptide Therapy Sales Market Share by Manufacturers (2018-2023)
2.2 Global Peptide Therapy Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Peptide Therapy Average Price by Manufacturers (2018-2023)
2.4 Global Peptide Therapy Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Peptide Therapy, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Peptide Therapy, Product Type & Application
2.7 Peptide Therapy Market Competitive Situation and Trends
2.7.1 Peptide Therapy Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Peptide Therapy Players Market Share by Revenue
2.7.3 Global Peptide Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Peptide Therapy Retrospective Market Scenario by Region
3.1 Global Peptide Therapy Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Peptide Therapy Global Peptide Therapy Sales by Region: 2018-2029
3.2.1 Global Peptide Therapy Sales by Region: 2018-2023
3.2.2 Global Peptide Therapy Sales by Region: 2024-2029
3.3 Global Peptide Therapy Global Peptide Therapy Revenue by Region: 2018-2029
3.3.1 Global Peptide Therapy Revenue by Region: 2018-2023
3.3.2 Global Peptide Therapy Revenue by Region: 2024-2029
3.4 North America Peptide Therapy Market Facts & Figures by Country
3.4.1 North America Peptide Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Peptide Therapy Sales by Country (2018-2029)
3.4.3 North America Peptide Therapy Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Peptide Therapy Market Facts & Figures by Country
3.5.1 Europe Peptide Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Peptide Therapy Sales by Country (2018-2029)
3.5.3 Europe Peptide Therapy Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Peptide Therapy Market Facts & Figures by Country
3.6.1 Asia Pacific Peptide Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Peptide Therapy Sales by Country (2018-2029)
3.6.3 Asia Pacific Peptide Therapy Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Peptide Therapy Market Facts & Figures by Country
3.7.1 Latin America Peptide Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Peptide Therapy Sales by Country (2018-2029)
3.7.3 Latin America Peptide Therapy Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Peptide Therapy Market Facts & Figures by Country
3.8.1 Middle East and Africa Peptide Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Peptide Therapy Sales by Country (2018-2029)
3.8.3 Middle East and Africa Peptide Therapy Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Peptide Therapy Sales by Type (2018-2029)
4.1.1 Global Peptide Therapy Sales by Type (2018-2023)
4.1.2 Global Peptide Therapy Sales by Type (2024-2029)
4.1.3 Global Peptide Therapy Sales Market Share by Type (2018-2029)
4.2 Global Peptide Therapy Revenue by Type (2018-2029)
4.2.1 Global Peptide Therapy Revenue by Type (2018-2023)
4.2.2 Global Peptide Therapy Revenue by Type (2024-2029)
4.2.3 Global Peptide Therapy Revenue Market Share by Type (2018-2029)
4.3 Global Peptide Therapy Price by Type (2018-2029)
5 Segment by Application
5.1 Global Peptide Therapy Sales by Application (2018-2029)
5.1.1 Global Peptide Therapy Sales by Application (2018-2023)
5.1.2 Global Peptide Therapy Sales by Application (2024-2029)
5.1.3 Global Peptide Therapy Sales Market Share by Application (2018-2029)
5.2 Global Peptide Therapy Revenue by Application (2018-2029)
5.2.1 Global Peptide Therapy Revenue by Application (2018-2023)
5.2.2 Global Peptide Therapy Revenue by Application (2024-2029)
5.2.3 Global Peptide Therapy Revenue Market Share by Application (2018-2029)
5.3 Global Peptide Therapy Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Corporation Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Eli Lilly Peptide Therapy Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.2.4 AstraZeneca Peptide Therapy Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Merck
6.3.1 Merck Corporation Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Merck Peptide Therapy Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Ipsen
6.4.1 Ipsen Corporation Information
6.4.2 Ipsen Description and Business Overview
6.4.3 Ipsen Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Ipsen Peptide Therapy Product Portfolio
6.4.5 Ipsen Recent Developments/Updates
6.5 Novo Nordisk
6.5.1 Novo Nordisk Corporation Information
6.5.2 Novo Nordisk Description and Business Overview
6.5.3 Novo Nordisk Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Novo Nordisk Peptide Therapy Product Portfolio
6.5.5 Novo Nordisk Recent Developments/Updates
6.6 Teva Pharmaceutical Industries
6.6.1 Teva Pharmaceutical Industries Corporation Information
6.6.2 Teva Pharmaceutical Industries Description and Business Overview
6.6.3 Teva Pharmaceutical Industries Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Teva Pharmaceutical Industries Peptide Therapy Product Portfolio
6.6.5 Teva Pharmaceutical Industries Recent Developments/Updates
6.7 Abbott Laboratories
6.6.1 Abbott Laboratories Corporation Information
6.6.2 Abbott Laboratories Description and Business Overview
6.6.3 Abbott Laboratories Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Abbott Laboratories Peptide Therapy Product Portfolio
6.7.5 Abbott Laboratories Recent Developments/Updates
6.8 Sanofi
6.8.1 Sanofi Corporation Information
6.8.2 Sanofi Description and Business Overview
6.8.3 Sanofi Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Sanofi Peptide Therapy Product Portfolio
6.8.5 Sanofi Recent Developments/Updates
6.9 J & J
6.9.1 J & J Corporation Information
6.9.2 J & J Description and Business Overview
6.9.3 J & J Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.9.4 J & J Peptide Therapy Product Portfolio
6.9.5 J & J Recent Developments/Updates
6.10 Novartis
6.10.1 Novartis Corporation Information
6.10.2 Novartis Description and Business Overview
6.10.3 Novartis Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Novartis Peptide Therapy Product Portfolio
6.10.5 Novartis Recent Developments/Updates
6.11 Takeda
6.11.1 Takeda Corporation Information
6.11.2 Takeda Peptide Therapy Description and Business Overview
6.11.3 Takeda Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Takeda Peptide Therapy Product Portfolio
6.11.5 Takeda Recent Developments/Updates
6.12 Ferring
6.12.1 Ferring Corporation Information
6.12.2 Ferring Peptide Therapy Description and Business Overview
6.12.3 Ferring Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Ferring Peptide Therapy Product Portfolio
6.12.5 Ferring Recent Developments/Updates
6.13 AbbVie
6.13.1 AbbVie Corporation Information
6.13.2 AbbVie Peptide Therapy Description and Business Overview
6.13.3 AbbVie Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.13.4 AbbVie Peptide Therapy Product Portfolio
6.13.5 AbbVie Recent Developments/Updates
6.14 Heinis
6.14.1 Heinis Corporation Information
6.14.2 Heinis Peptide Therapy Description and Business Overview
6.14.3 Heinis Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Heinis Peptide Therapy Product Portfolio
6.14.5 Heinis Recent Developments/Updates
6.15 Hemmo
6.15.1 Hemmo Corporation Information
6.15.2 Hemmo Peptide Therapy Description and Business Overview
6.15.3 Hemmo Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Hemmo Peptide Therapy Product Portfolio
6.15.5 Hemmo Recent Developments/Updates
6.16 Emcure Pharmaceutical
6.16.1 Emcure Pharmaceutical Corporation Information
6.16.2 Emcure Pharmaceutical Peptide Therapy Description and Business Overview
6.16.3 Emcure Pharmaceutical Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Emcure Pharmaceutical Peptide Therapy Product Portfolio
6.16.5 Emcure Pharmaceutical Recent Developments/Updates
6.17 Cipla
6.17.1 Cipla Corporation Information
6.17.2 Cipla Peptide Therapy Description and Business Overview
6.17.3 Cipla Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Cipla Peptide Therapy Product Portfolio
6.17.5 Cipla Recent Developments/Updates
6.18 Gland Pharma
6.18.1 Gland Pharma Corporation Information
6.18.2 Gland Pharma Peptide Therapy Description and Business Overview
6.18.3 Gland Pharma Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Gland Pharma Peptide Therapy Product Portfolio
6.18.5 Gland Pharma Recent Developments/Updates
6.19 Troikaa Pharmaceuticals
6.19.1 Troikaa Pharmaceuticals Corporation Information
6.19.2 Troikaa Pharmaceuticals Peptide Therapy Description and Business Overview
6.19.3 Troikaa Pharmaceuticals Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Troikaa Pharmaceuticals Peptide Therapy Product Portfolio
6.19.5 Troikaa Pharmaceuticals Recent Developments/Updates
6.20 Biological E
6.20.1 Biological E Corporation Information
6.20.2 Biological E Peptide Therapy Description and Business Overview
6.20.3 Biological E Peptide Therapy Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Biological E Peptide Therapy Product Portfolio
6.20.5 Biological E Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Peptide Therapy Industry Chain Analysis
7.2 Peptide Therapy Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Peptide Therapy Production Mode & Process
7.4 Peptide Therapy Sales and Marketing
7.4.1 Peptide Therapy Sales Channels
7.4.2 Peptide Therapy Distributors
7.5 Peptide Therapy Customers
8 Peptide Therapy Market Dynamics
8.1 Peptide Therapy Industry Trends
8.2 Peptide Therapy Market Drivers
8.3 Peptide Therapy Market Challenges
8.4 Peptide Therapy Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock